Brii Biosciences

Explore the latest insights on Brii Biosciences and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Brii Biosciences’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Explore the latest insights on Brii Biosciences and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Brii Biosciences's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Biostar's Oral Utidelone Capsule Achieves First Patient Dosing in Phase 3 – Non‑Inferiority Bridging Study vs. Marketed Utidelone Injection in HER2‑Negative Advanced Breast Cancer
CompanyDrug

Biostar’s Oral Utidelone Capsule Achieves First Patient Dosing in Phase 3 – Non‑Inferiority Bridging Study vs. Marketed Utidelone Injection in HER2‑Negative Advanced Breast Cancer

Beijing Biostar Pharmaceuticals Co., Ltd. (HKG: 2563) announced that its core pipeline asset Utidelone Capsule (UTD2) has successfully achieved first patient dosing in the Phase 3 clinical study (BG02‑2601) for…

Bao Pharmaceuticals’ BJ045 Wins NMPA Clinical Trial Approval – Enzyme‑Resistant Subcutaneous Anti‑CD20 Antibody Engineered for Combination With IgG‑Degrading KJ103

Sanofi and Teva Present 44‑Week RELIEVE UCCD Extension Data – TL1A Antibody Duvakitug Sustains Efficacy Across Ulcerative Colitis and Crohn's Disease Endpoints

Sanofi and Teva Present 44‑Week RELIEVE UCCD Extension Data – TL1A Antibody Duvakitug Sustains Efficacy Across Ulcerative Colitis and Crohn’s Disease Endpoints

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Brii Biosciences’ COVID-19 Antibody Cocktail Effective Against Omicron BA.4/5 and BA.2.12.1

CompanyDeals

Brii Biosciences Partners with Huarun Medicine to Commercialize COVID-19 Antibody Cocktail in China

CompanyDrug

Brii Biosciences Launches Anti-COVID-19 Antibody Cocktail in China

CompanyDeals

Brii Biosciences Exercises Option for VIR-3434 in Greater China

Show More